GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
0.283
+0.003 (1.07%)
At close: Apr 28, 2026, 4:00 PM EDT
0.290
+0.007 (2.51%)
After-hours: Apr 28, 2026, 7:56 PM EDT
GT Biopharma Employees
GT Biopharma had 1 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
1
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$34,449,000
Market Cap
8.93M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| Bolt Biotherapeutics | 23 |
| CalciMedica | 16 |
| Genprex | 13 |
| NuCana | 12 |
| Processa Pharmaceuticals | 12 |
| MetaVia | 8 |
| Quoin Pharmaceuticals | 5 |
GTBP News
- 12 days ago - GT Biopharma Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators - Transcripts
- 2 months ago - GT Biopharma Reports Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference - GlobeNewsWire
- 3 months ago - GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3 - GlobeNewsWire
- 3 months ago - GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers - GlobeNewsWire
- 3 months ago - EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment - Benzinga
- 4 months ago - Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 - PRNewsWire
- 5 months ago - GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials - Accesswire